underhållets processer och ledarskap › _files › 200001731... · astrazeneca: global dimensions...
TRANSCRIPT
![Page 1: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/1.jpg)
Underhålletsprocesser ochledarskap
Jerry Johansson
4th of October 2019
![Page 2: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/2.jpg)
Agenda:
AstraZeneca
OrganisationQuality systemProcess ManagementLean/TPMQ&A
![Page 3: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/3.jpg)
30 September 2019Speaker Kit
AstraZeneca: global dimensionsFor year ending 31 December 2018
$22.1bn $5.9bn 64.6k
$21.1bn 149 45%
$1bn 23 30
Total Revenue(down 2% over 2017)
invested in R&D with research across five countries
Product Sales(up 4% over 2017)
projects in clinical development and eight NMEs in late-stage development
of our senior roles are filled by women
Externalisation Revenue
NME approvals in 2018 (and 71 since 2014)
operations sites in 17 countries
employees
3
![Page 4: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/4.jpg)
01
0304
05
06
07
08
09
10
1112
13
14
15
16
17
18
19
20
1. Lomas Verdes (Mexico)
2. Boulder (Colorado, USA)
3. Mt Vernon (Indiana, USA)
4. West Chester (Ohio, USA)
5. Newark, Frederick, Maryland,
Philadelphia, Westborough (USA)
6. Canovanas (Puerto Rico)
7. Buenos Aires (Argentina)
8. Cotia (Brazil)
9. Avlon, Macclesfield, Speke (UK)
10. Reims, Dunkerque (France)
11. Nijmegen (Netherlands)
12. Wedel (Germany)
13. Södertälje: Snäckviken & Gärtuna
(Sweden) + Biologics
14. Cairo (Eqypt)
15. Vorsino (Russia)
16. Bangalore (India)
17. Jakarta (Indonesia)
18. Taizhou, Wuxi (China)
19. Maihara (Japan)
20. North Ryde (Australia)
02
![Page 5: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/5.jpg)
Gothenburg
AstraZeneca in Gothenburg
30 September 2019Speaker Kit5
Supporting our three main therapy areasand the full R&D value chain
![Page 6: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/6.jpg)
Södertälje
AstraZeneca in Södertälje
30 September 2019Speaker Kit6
AstraZeneca’s largest high-tech manufacturing and supply site include manufacturing of active pharmaceutical
ingredients, formulation, tableting, filling and packing of finished products
![Page 7: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/7.jpg)
AstraZeneca Sweden Operations
![Page 8: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/8.jpg)
Sweden Operations products
• Turbuhaler
Symbicort, Pulmicort, Oxis
• Tablets
• Capsules
Nexium, Losec, Seloken och Atacand.
• Pumpspray
• Solutions for injektion
Rhinocort Aqua och Nexium i.v.
• API
![Page 9: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/9.jpg)
Our vision
There are no break downs at AstraZeneca, caused by lack of maintenance.
A break down due to lack of maintenance or competence is a failure for the
maintenance organization.
We are the best within AstraZeneca in delivering capital projects .
In time
To the right cost
With the right function
![Page 10: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/10.jpg)
authority requirements
Code of conduct
Policies
Standards
Standards
Regulations
Guidelines
Regional demand for
Sweden Operations
AstraZeneca demand
All pharma companiesMaintenance has
+300 written standards SOPs
Yearly training must be done
Updates are controlled by Q
![Page 11: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/11.jpg)
11
Kvalitet är ett holistiskt begrepp
Product & Process Design
✓ Components, Unit Operations
Control Strategy for Critical Quality
Attributes
✓ Process Parameter set points and
ranges, In-process testing, Finished
Product testing
Quality is everything
QMS
Say what you do
Do what you say
Prove it
Improve it
Regulatory Compliance
✓ Specifications, Product Design,
Manufacturing Process
Legislation
✓ GMP
![Page 12: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/12.jpg)
12
How du we control/develop our maintenance system?
![Page 13: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/13.jpg)
Our main processes
13
Early
Equipment
Management
Perform
Maintenance
Face out and
reinvestment
![Page 14: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/14.jpg)
Early Equipment Management
![Page 15: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/15.jpg)
15
Plan Do Check
Analyze
![Page 16: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/16.jpg)
The Lean Journey Sweden Operations
![Page 17: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/17.jpg)
TPM Strategy
![Page 18: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/18.jpg)
Basic (future) requirements for an operator in EMEA( agreed with representatives from all sites Europe )
18
An operator must/should be able to:
- Run, adjust, set up and improve the line/machine/equipment
- Solve problems by using Problem Solving
- Develop, follow and improve standards by using Standard Work and CI
- Clean, lubricate and inspect - the base of Autonomous Maintenance(AM)
With increased operating competence we will develop engagement and ownership
and can also introduce formal Equipment Ownership for our operators.
![Page 19: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/19.jpg)
All linked together!
.
![Page 20: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/20.jpg)
Key initiatives
20
• Competence development
• Maintenance development
• Investment plans
• Smart Maintenance/digitalization
![Page 21: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/21.jpg)
AI can that help us understand things we
normaly cant understand?
21
![Page 22: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/22.jpg)
22
Upplägg på projektet
3 utrustningar
2 år historisk data
3 IT-system
PIS• Processdata:
• Temperatur
• Luftflöde
• Tryck
• Produktionsdata:• Batchstorlek
• Receptfas
WO from
Maintenace
system
Production
Parameters
![Page 23: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/23.jpg)
23
Deep dive: Hur gjorde vi?
Anomaly
detection
Failure detection
![Page 24: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/24.jpg)
Our industry is changing
24
Contract manufacturer
No blockbuster?
Personalized medicine, smaller series
Our efficiency must up!
No “Losec” can save us in the future…..
![Page 25: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/25.jpg)
Fokus areas for maintenance
• Right Maintenance Strategy
• Competence development
• Planning and execution of maintenance
Shorter and more efficient stop
Higher flexibility
&
KPIs and structure for follow up.
Clear ownership of the availability
25
![Page 26: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/26.jpg)
26
Questions?
![Page 27: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/27.jpg)
Successful management
27
• Organization form is not important
Clear objectives and the management defines the result.
• Work together with production!
• We have all the tools we need!
It's all about usage.
![Page 28: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/28.jpg)
so if you would like to have
28
• Highly motivated teams
• Collaboration between groups
• Groups with a desire to achieve the best in class (WCM).
I am really glad if I inspired you and can help you in the
future.
![Page 29: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/29.jpg)
29
Jerry Johansson HEAD OF EMA Engineering Maintenance and Asset Management _____________________________________________________________ AstraZeneca Sweden Operations | E.M.A | Maintenance Strategy and Governance SE-151 85 Södertälje, Sweden Telephone: +46 8 553 21389 Mobile: +46 70 5289177 [email protected]
![Page 30: Underhållets processer och ledarskap › _files › 200001731... · AstraZeneca: global dimensions For year ending 31 December 2018 $ 22.1 bn $5.9 bn 64.6 k $ 21.1 bn 149 45 % $](https://reader033.vdocuments.mx/reader033/viewer/2022052500/5f0ee4117e708231d4417170/html5/thumbnails/30.jpg)
Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com
30